生物标志物在局限性肾癌术后预后判断中的价值  

Value of biomarkers in prognosis of localized renal carcinoma after surgery

作　　者：任有为(综述) 管晓东(审校) REN Youwei;GUAN Xiaodong(Changzhi Medical College,Changzhi,Shanxi 046000,China;Department of Urology,Yuncheng Central Hospital of Shanxi Province,Yuncheng,Shanxi 044000,China)

机构地区：[1]长治医学院,山西长治046000 [2]山西省运城市中心医院泌尿外科,山西运城044000

出　　处：《检验医学与临床》2023年第10期1462-1466,共5页Laboratory Medicine and Clinic

摘　　要：肾癌是泌尿系统最常见和最致命的恶性肿瘤之一,并且在组织学、遗传学和肿瘤行为方面存在异质性,其发病机制复杂,发病率已连续20年上升。目前,除了分级和分期的组织学标准外,缺乏用于评估肾癌预后的生物标志物,该文就癌基因和相关预后模型、微小RNA、循环肿瘤DNA和循环游离DNA、程序性死亡配体-1在局限性肾癌患者肾切除术后的预后判断价值进行综述。Renal carcinoma is one of the most common and deadly malignancies of the urinary system.It is heterogeneous in histology,genetics and tumor behavior.Its pathogenesis is complex and its incidence has been increasing for 20 years.In addition to histological criteria for grading and staging,biomarkers for evaluating renal cancer prognosis are currently lacking.This review reviews the prognostic value of oncogenes and associated prognostic models,microRNA,circulating tumor DNA and circulating free DNA and procedural death ligand-1 in patients with localized renal cancer after nephrectomy.

关 键 词：肾癌 癌基因 预后 微小RNA DNA 程序性死亡配体-1 

分 类 号：R737.11[医药卫生—肿瘤]